Home / Reports

Reports

European drug seizures criticised in Oxfam/HAI report

EU trade policies regulating the pharmaceutical industry, including the seizure of generic drugs in transit to developing countries, are supporting the commercial interests of some drugmakers while damaging opportunities for innovation and access to medicines in developing countries, an Oxfam International and Health Action International (HAI) report says. The report criticizes recent European customs authorities’ seizures of generic drugs suspected of infringing intellectual property rights.

The world market for biosimilars and their potential in the US

Kalorama Information published a new report on biosimilars, World Market for Biosimilars and the Potential for US Follow-on Biologics on 1 August 2009, based on interviews in the ‘biogeneric’ drug industry and an extensive literature study.

Accenture report: biosimilars offer chances despite risks

According to the report Biosimilars – Emergence of a third market dynamic between original products and generics published by the global management consultancy, Accenture, the biosimilars market will open up interesting opportunities for pharmaceutical and generic companies despite significant risks.

Emerging market for biosimilars and biobetters

The Biophoenix report Biosimilars and Biobetters: Positioning for a New Market published on 9 July 2009 reveals that biosimilar sales may reach US$6 billion (Euros 4.2 billion) by 2013 as regulatory frameworks take shape.

EU will act against drugmakers that delay generics

The European Commission (EC) released its final report on 8 July 2009 concerning competition in the pharmaceutical sector, and said it will increase its oversight of the industry after finding that drugmakers' business practices contributed to the delay of generic drugs being introduced to the market. The EC explained that “to reduce the risk that settlements between originator and generic companies are concluded at the expense of consumers, the EC undertakes to carry out further focused monitoring of settlements that limit or delay the market entry of generic drugs”. Furthermore, it will not hesitate to act against ‘anticompetitive practices’ by drugmakers that delay the market entry of generics, but has also called on Member States to do more to boost generic uptake.

Blockbuster biologicals in 2008 possible targets for new biosimilars?

With the recently introduced two US biosimilar bills and the expectation that a US biosimilars pathway will be realised before the end of this year, the race for biosimilar (or biobetter) versions of extremely expensive biologicals that will soon go off-patent has really begun.

EGA report: Increase patient access to generic medicines

“EU governments need to ensure fast generic medicines uptake, as market access and low market volume in key EU countries is still a real problem and is having a major negative impact on patient access to more affordable treatments”, argues a new report of the European Generic medicines Association (EGA), entitled How to Increase Patient Access to Generic Medicines in European Healthcare Systems.

European biosimilars market set to grow gradually

A new report from Frost & Sullivan (F&S) has claimed that despite the initial regulatory hiccups, the number of biosimilars in the European market is set to increase gradually. It notes that patent expiries of key biopharmaceuticals have opened up numerous lucrative market opportunities, while driving the development of biosimilars. In addition, payers' perception of biosimilars, as viable alternatives to originator drugs due to their safety, efficacy and affordability, will further bolster market prospects.